Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Study Status: Enrolling
What is the purpose of this study?
The purpose of this research study is to evaluate the safety of treating eyes and assess if GS010 is able to improve vision or prevent further vision loss caused by LHON from the ND4 gene mutation. This will be done by various tests and assessments of your eyes and vision, which will be described in more detail later. The investigational drug that you will receive in this study is currently referred to as GS010. Investigational means that the drug has not been approved yet for marketing by any regulatory agency anywhere in the world
What will I have to do if I take part in this study?
This study enrolled participants who had a specific gene mutation for Leber Hereditary Optic Neuropathy (LHON) which causes visual loss in both eyes.
Is this the right trial for me?
This study enrolled participants who had a specific gene mutation for Leber Hereditary Optic Neuropathy (LHON) which causes visual loss in both eyes.
For additional information
- Principal Investigator: Nancy J. Newman, MD
- Trial Coordinator: Lindy DuBois, MEd, MMSc